ArticleTranslational vision science & technology2024
Artificial Intelligence-Assisted Perfusion Density as Biomarker for Screening Diabetic Nephropathy.
Article in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Evaluation of retinochoroidal changes after implantable collamer lens implantation: insights from UWF-SS-OCTA and AI-based 3D modeling.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Progress on exercise therapy in type 2 diabetes mellitus with cognitive impairment.Frontiers in sports and active living · 2026Review
- Ocular biomarkers in diabetes mellitus with diabetic kidney disease: A minireview.World journal of nephrology · 2025Review
- Comments on Xie et al.'s Study on Artificial Intelligence-Assisted Perfusion Density as Biomarker for Screening Diabetic Nephropathy.Translational vision science & technology · 2025Article
- Retinal vessel metric analysis of type 1 diabetes mellitus in OCT angiography.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify a reliable biomarker for screening diabetic nephropathy (DN) using artificial intelligence (AI)-assisted ultra-widefield swept-source optical coherence tomography angiography (UWF SS-OCTA). Methods: This study analyzed data from 169 patients (287 eyes) with type 2 diabetes mellitus (T2DM), resulting in 15,211 individual data points. These data points included basic demographic information, clinical data, and retinal and choroidal data obtained through UWF SS-OCTA for each eye. Statistical analysis, 10-fold cross-validation, and the random forest approach were employed for data processing. Results: The degree of retinal microvascular damage in the diabetic retinopathy (DR) with the DN group was significantly greater than in the DR without DN group, as measured by SS-OCTA parameters. There were strong associations between perfusion density (PD) and DN diagnosis in both the T2DM population (r = -0.562 to -0.481, P < 0.001) and the DR population (r = -0.397 to -0.357, P < 0.001). The random forest model showed an average classification accuracy of 85.8442% for identifying DN patients based on perfusion density in the T2DM population and 82.5739% in the DR population. Conclusions: Quantitative analysis of microvasculature reveals a correlation between DR and DN. UWF PD may serve as a significant and noninvasive biomarker for evaluating DN in patients through deep learning. AI-assisted SS-OCTA could be a rapid and reliable tool for screening DN. Translational Relevance: We aim to study the pathological processes of DR and DN and determine the correspondence between their clinical and pathological manifestations to further clarify the potential of screening DN using AI-assisted UWF PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.